Berenberg Downgrades Bristol-Myers Squibb Co. (BMY) to Hold
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Berenberg downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Hold with a price target of $70.00.
Analyst Laura Sutcliffe commented, "One of the key risks to the short-term Buy case for Bristol has crystallised. Following the failure of CheckMate 026 – which evaluated IO drug Opdivo as monotherapy in first-line NSCLC in PD-L1 positive patients – we downgrade our recommendation for Bristol from Buy to Hold. While a lack of success in this particular trial has no impact on about half of Bristol’s IO opportunity, it affects the NSCLC space as a whole, and places Bristol on the back foot in a market where it has, up until now, dominated."
Shares of Bristol-Myers Squibb Co. closed at $60.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Argus Downgrades Abercrombie & Fitch (ANF) to Sell
- Credit Suisse Upgrades CVR Refining (CVRR) to Outperform; Most Exposed to RINs
- BMO Capital Cuts Price Target on Nielsen Holdings (NLSN) to $45
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!